Axicabtagene Ciloleucel

CHEMBL3989989 Phase 4 معتمد Gene

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A CAR-T cell therapy in which a patient's own T cells are genetically engineered to express a chimeric antigen receptor targeting CD19, a protein on the surface of certain B-cell cancers. The modified cells are infused back to seek out and destroy cancer cells.

المجالات العلاجية

Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A CAR-T cell therapy in which a patient's own T cells are genetically engineered to express a chimeric antigen receptor targeting CD19, a protein on the surface of certain B-cell cancers. The modified cells are infused back to seek out and destroy cancer cells.

Yes, Axicabtagene Ciloleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989989. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Axicabtagene Ciloleucel على PillFYI

بيانات سريعة

المرادفات: 1

روابط خارجية

ChEMBL CHEMBL3989989

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.